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LETTER FROM DR. KENNETH WILSON
Re: Systemic therapy for patients at high risk for re-
current melanoma. Verma S., Quirt I., McCready
D., Charette M., Iscoe N. and the members of the
Melanoma Disease Site Group. Curr Oncol 2005;
12:31–6.
The conclusions reached in this review are based on
incomplete data. In June 2002, the Melanoma Dis-
ease Site Group (DSG) sent me a draft manuscript of
the above paper to review. I specifically recom-
mended that the proposed guideline should reflect
the fact that the E1684 trial is negative for overall
survival benefit for high-dose interferon (HDIFN) at a
median follow-up of 12.6 years (one-sided p value
0.09, as dictated by the protocol). Dr. John Kirkwood,
principal investigator of the E1684 trial, provided a
p value for overall survival in a letter to J Clin Oncol
2001 in response to a letter of mine seeking same.
Unfortunately, Dr. Kirkwood, like the DSG, contin-
ues to interpret E1684 as a positive study, in spite of
the insignificant p value with mature follow-up*. Al-
though the E1684 investigators point to competing
causes of death, they have not analyzed disease-spe-
cific mortality—or if they have, they have not re-
ported it. They have reported analysis of distant
disease-free survival, but this was not a protocol-
specified endpoint. During manuscript review, I rec-
ommended that the DSG obtain the 12.6-year
follow-up data of E1684 to add to their database and
conduct joint analysis with other ECOG trials. The DSG
have not acknowledged this important follow-up data
on E1684 in their guideline. In fact, they reiterate
that the ECOG 1684 trial detected a significant im-
provement in overall survival after “prolonged fol-
low-up.” This was in spite of being advised that
analysis at a median follow-up of 12.6 years is nega-
tive (p = 0.09) for overall survival benefit. Conse-
quently, we now have two mature ECOG studies of
adjuvant HDIFN that are negative for overall survival
benefit.
I believe that the results of E1694 are too pre-
liminary to conclude that HDIFN is superior to GMK
vaccine as adjuvant therapy of high-risk melanoma.
The importance of mature follow-up is amply dem-
onstrated by the E1684 experience. Indeed, the ab-
sence of published follow-up data on the E1694 trial
makes one wonder whether the preliminary results
are sustained.
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REPLY FROM DR. SHAILENDRA VERMA
Thank you for your comments. We acknowledge and
concur with your opinion regarding the assertion that
high-dose interferon is associated with a significant
survival benefit. Our guideline has been corrected to
reflect this, and the latest iteration states that “Our
review of the available literature identified no sys-
temic adjuvant therapy that confers a significant sur-
vival benefit in patients with high-risk resected
primary melanoma. However high-dose interferon
treatment should be considered in such patients as
such therapy is associated with significant improve-
ment in disease-free survival and reduction in 2-year
mortality.”
Shail Verma MD, Co-Chair, Melanoma Disease Site
Group, Cancer Care Ontario Practice Guidelines Ini-
tiative, Program in Evidence-based Care, McMaster
University, 3rd Floor, 1280 Main Street West, Hamil-
ton, Ontario L8S 4L8
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